Compare MasTec Inc (MTZ) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MasTec Inc vs Natera Inc. Common Stock — how do they compare? MasTec Inc trades at $191.47 (market cap $15.62B), while Natera Inc. Common Stock trades at $393.93 (market cap $57.03B). The key difference: Natera Inc. Common Stock is far larger — about 3.7× MasTec Inc's market cap, and Natera Inc. Common Stock is trading nearer its 52-week high, MasTec Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold MasTec Inc for 25 Days and Natera Inc. Common Stock for 0 Days on average.
| MTZ | NTRA | |
|---|---|---|
Market Cap | $15.62B | $57.03B |
Volume | 1,770,191 | 1,131,157 |
Sector | Industrials | Health |
52-Week High | $437.51 | $425.64 |
52-Week Low | $190.08 | $179.42 |
Typical Hold Time | 25 Days | 0 Days |
Enterprise Value | $18.54B | $56.18B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MasTec (MTZ) trades at $206.12, down 0.35% on the day, with a bearish technical signal despite strong analyst support. The stock shows mixed fundamentals with a P/E of 30.96 and P/S of 0.95, while recent earnings beat expectations in two of the last three quarters. The company benefits from record backlog growth and infrastructure investment cycles, particularly in power delivery and data center markets, though cash flow trends show volatility between periods.
The outlook remains positive with 89% analyst buy ratings and a $403.92 consensus price target suggesting significant upside potential. Key risks include premium valuation concerns, communications segment softness, and execution challenges in managing rapid backlog growth. Infrastructure demand drivers provide strong tailwinds, but investors should monitor cash flow improvement and margin sustainability.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About MasTec Inc
MasTec, Inc. is a leading infrastructure construction company operating mainly in North America. The company's services cover a diverse range of end-markets, including communications (building fiber and wireless infrastructure), oil & gas, electric power (transmission, distribution, and clean energy), and industrial projects. MTZ provides critical engineering, procurement, and construction (EPC) services that support the expansion and maintenance of essential infrastructure across the continent.
Read more on MTZ →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
